Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (19182) 19182
Dissertation (40) 40
Book Chapter (34) 34
Magazine Article (19) 19
Conference Proceeding (16) 16
Book / eBook (12) 12
Publication (9) 9
Web Resource (4) 4
Government Document (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (13745) 13745
science & technology (12082) 12082
life sciences & biomedicine (11329) 11329
quinazolines - pharmacology (7688) 7688
female (6706) 6706
male (6287) 6287
quinazolines - therapeutic use (6010) 6010
animals (5957) 5957
oncology (5867) 5867
biological and medical sciences (4522) 4522
medical sciences (4248) 4248
middle aged (4133) 4133
aged (3566) 3566
lung neoplasms - drug therapy (3472) 3472
quinazolines - administration & dosage (3263) 3263
adult (3065) 3065
receptor, epidermal growth factor - antagonists & inhibitors (2997) 2997
cell line, tumor (2854) 2854
mice (2836) 2836
antineoplastic agents - therapeutic use (2798) 2798
carcinoma, non-small-cell lung - drug therapy (2793) 2793
pharmacology. drug treatments (2711) 2711
erlotinib hydrochloride (2685) 2685
pharmacology & pharmacy (2507) 2507
quinazolines - adverse effects (2327) 2327
antineoplastic agents - pharmacology (2265) 2265
tumors (2196) 2196
gefitinib (2037) 2037
antineoplastic agents (2022) 2022
treatment outcome (1952) 1952
quinazolines - chemistry (1931) 1931
receptor, epidermal growth factor - genetics (1832) 1832
cancer (1807) 1807
mutation (1761) 1761
protein kinase inhibitors - therapeutic use (1737) 1737
receptor, epidermal growth factor - metabolism (1715) 1715
rats (1707) 1707
antineoplastic combined chemotherapy protocols - therapeutic use (1657) 1657
lung neoplasms - pathology (1623) 1623
protein kinase inhibitors - pharmacology (1594) 1594
dose-response relationship, drug (1564) 1564
quinazolines - chemical synthesis (1559) 1559
lung neoplasms - genetics (1482) 1482
chemistry (1465) 1465
epidermal growth factor (1446) 1446
chemotherapy (1430) 1430
quinazolines (1388) 1388
cell proliferation - drug effects (1366) 1366
aged, 80 and over (1327) 1327
biochemistry & molecular biology (1306) 1306
analysis (1210) 1210
care and treatment (1175) 1175
lung cancer (1161) 1161
erlotinib (1149) 1149
carcinoma, non-small-cell lung - pathology (1145) 1145
structure-activity relationship (1143) 1143
carcinoma, non-small-cell lung - genetics (1136) 1136
research (1129) 1129
signal transduction - drug effects (1093) 1093
physical sciences (1092) 1092
apoptosis - drug effects (1069) 1069
egfr (1052) 1052
breast neoplasms - drug therapy (1044) 1044
adenocarcinoma - drug therapy (985) 985
enzyme inhibitors - pharmacology (978) 978
cell biology (972) 972
phosphorylation (956) 956
quinazolines - pharmacokinetics (951) 951
lung cancer, non-small cell (950) 950
antineoplastic agents - adverse effects (940) 940
signal transduction (924) 924
disease-free survival (899) 899
tyrosine (868) 868
drug resistance, neoplasm (858) 858
breast cancer (855) 855
time factors (838) 838
apoptosis (831) 831
epidermal growth factor receptor (819) 819
molecular structure (815) 815
abridged index medicus (808) 808
kinases (799) 799
respiratory system (786) 786
pneumology (776) 776
mice, nude (766) 766
quinazoline (760) 760
chemistry, medicinal (758) 758
tumors of the respiratory system and mediastinum (756) 756
hematology, oncology and palliative medicine (748) 748
clinical trials as topic (734) 734
neoplasm staging (730) 730
medicine & public health (728) 728
drug therapy (727) 727
xenograft model antitumor assays (724) 724
antibodies, monoclonal, humanized (720) 720
prognosis (705) 705
tumor cells, cultured (675) 675
tyrphostins - pharmacology (673) 673
antineoplastic agents - administration & dosage (668) 668
quinazolines - metabolism (659) 659
receptor, erbb-2 - metabolism (659) 659
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (18239) 18239
Japanese (498) 498
Chinese (322) 322
German (273) 273
French (190) 190
Russian (84) 84
Spanish (82) 82
Italian (78) 78
Hungarian (44) 44
Polish (31) 31
Portuguese (30) 30
Czech (27) 27
Ukrainian (16) 16
Danish (12) 12
Dutch (9) 9
Norwegian (9) 9
Finnish (4) 4
Korean (4) 4
Romanian (4) 4
Bulgarian (3) 3
Croatian (3) 3
Hebrew (3) 3
Arabic (2) 2
Swedish (2) 2
Turkish (2) 2
Indonesian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. A Series of 2,4(1H,3H)-Quinazolinedione derivatives: Synthesis and biological evaluation as potential anticancer agents
by Akgun, Hulya and Yilmaz, Demet Us and Atalay, Rengul Cetin and Gozen, Damla
Letters in drug design & discovery, ISSN 1570-1808, 2016, Volume 13, Issue 1, pp. 64 - 76
Cytotoxicity | Sulforhodamine B method | Quinazoline | Anticancer | Quinazoline-2,4(1H,3H)-dione | Piperazine | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology
Journal Article
Details down arrow
2. Full Text Quinazolines and quinazolinones as ubiquitous structural fragments in medicinal chemistry: An update on the development of synthetic methods and pharmacological diversification
by Khan, Imtiaz and Zaib, Sumera and Batool, Sadaf and Abbas, Naeem and Ashraf, Zaman and Iqbal, Jamshed and Saeed, Aamer
Bioorganic & medicinal chemistry, ISSN 0968-0896, 06/2016, Volume 24, Issue 11, pp. 2361 - 2381
Heterocycles | Quinazolinones | Enzyme inhibitors | Drug discovery | Quinazolines | Biological activity | Biochemistry & Molecular Biology | Physical Sciences | Chemistry | Chemistry, Organic | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Chemistry, Medicinal | Science & Technology | Quinazolines - chemical synthesis | Quinazolinones - chemical synthesis | Animals | Humans | Quinazolinones - chemistry | Quinazolines - pharmacology | Quinazolines - chemistry | Chemistry, Pharmaceutical | Quinazolinones - pharmacology | Cytokinins | Enzymes | Epidermal growth factor | Monoamine oxidase | Analysis | Albumin | GABA | Fluorides | Methods | Sugars | Monosaccharides | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
by Stephen Johnston and John Pippen, Jr and Xavier Pivot and Mikhail Lichinitser and Saeed Sadeghi and Veronique Dieras and Henry Leonidas Gomez and Gilles Romieu and Alexey Manikhas and M. John Kennedy and Michael F. Press and Julie Maltzman and Allison Florance and Lisa O'Rourke and Cristina Oliva and Steven Stein and Mark Pegram
Journal of clinical oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 33, pp. 5538 - 5546
Life Sciences & Biomedicine | Oncology | Science & Technology | Triazoles - administration & dosage | Triazoles - adverse effects | Postmenopause - drug effects | Receptors, Estrogen - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma - mortality | Receptors, Progesterone - genetics | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Invasiveness - pathology | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma - pathology | Carcinoma - secondary | Carcinoma - drug therapy | Receptors, Estrogen - genetics | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Biomarkers, Tumor - analysis | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - pathology | Quinazolines - adverse effects | Survival Analysis | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Carcinoma - metabolism | Neoplasm Staging | Nitriles - adverse effects | Index Medicus | Carcinoma | Quinazolines | Breast Neoplasms | Life Sciences | Immunology | Triazoles | Postmenopause | Nitriles | Antineoplastic Agents, Hormonal | Tumor Markers, Biological | Receptors, Estrogen | Neoplasm Invasiveness | Antineoplastic Combined Chemotherapy Protocols | Receptor, erbB-2 | Receptors, Progesterone | Kaplan-Meiers Estimate
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Quinazolines: New horizons in anticonvulsant therapy
by Ugale, Vinod G and Bari, Sanjay B
European journal of medicinal chemistry, ISSN 0223-5234, 06/2014, Volume 80, pp. 447 - 501
Synthesis quinazoline | Anticonvulsant | MES | PTZ-induced seizure | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Quinazolines - chemical synthesis | Animals | Anticonvulsants - chemical synthesis | Anticonvulsants - chemistry | Humans | Drug Design | Quinazolines - pharmacology | Anticonvulsants - pharmacology | Quinazolines - chemistry | Anticonvulsants | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker
by Solca, Flavio and Dahl, Goeran and Zoephel, Andreas and Bader, Gerd and Sanderson, Michael and Klein, Christian and Kraemer, Oliver and Himmelsbach, Frank and Haaksma, Eric and Adolf, Guenther R
The Journal of pharmacology and experimental therapeutics, ISSN 0022-3565, 11/2012, Volume 343, Issue 2, pp. 342 - 350
Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Surface Plasmon Resonance | Data Interpretation, Statistical | Phosphorylation | Cell Proliferation | Genes, erbB - drug effects | Genes, erbB - genetics | Humans | Cells, Cultured | Models, Molecular | Molecular Sequence Data | Structure-Activity Relationship | Phosphotransferases - antagonists & inhibitors | Crystallography | Receptor, Epidermal Growth Factor - metabolism | Animals | Transfection | Quinazolines - metabolism | Protein Conformation | Mice | Receptor, ErbB-2 - antagonists & inhibitors | Quinazolines - pharmacology | Spectrum Analysis | Quinazolines - chemistry
Journal Article
Details down arrow
6. Full Text Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: Molecular docking study
by El-Azab, Adel S and Al-Omar, Mohamed A and Abdel-Aziz, Alaa A.-M and Abdel-Aziz, Naglaa I and El-Sayed, Magda A.-A and Aleisa, Abdulaziz M and Sayed-Ahmed, Mohamed M and Abdel-Hamide, Sami G
European journal of medicinal chemistry, ISSN 0223-5234, 2010, Volume 45, Issue 9, pp. 4188 - 4198
Drug-likeness | Synthesis | Quinazoline | Molecular docking | Antitumor | Biological and medical sciences | General aspects | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Quinazolines - chemical synthesis | Antineoplastic Agents - chemical synthesis | Humans | Models, Molecular | Structure-Activity Relationship | Antineoplastic Agents - chemistry | Static Electricity | Receptor, Epidermal Growth Factor - chemistry | Antineoplastic Agents - metabolism | Receptor, Epidermal Growth Factor - metabolism | Hydrogen Bonding | Quinazolines - metabolism | Drug Design | Cell Line, Tumor | Inhibitory Concentration 50 | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Protein Conformation | Antineoplastic Agents - pharmacology | Quinazolines - pharmacology | Quinazolines - chemistry | Antimitotic agents | Epidermal growth factor | Analysis | Pharmacy | Universities and colleges | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
by Lecia V. Sequist and James Chih-Hsin Yang and Nobuyuki Yamamoto and Kenneth O'Byrne and Vera Hirsh and Tony Mok and Sarayut Lucien Geater and Sergey Orlov and Chun-Ming Tsai and Michael Boyer and Wu-Chou Su and Jaafar Bennouna and Terufumi Kato and Vera Gorbunova and Ki Hyeong Lee and Riyaz Shah and Dan Massey and Victoria Zazulina and Mehdi Shahidi and Martin Schuler
Journal of clinical oncology, ISSN 0732-183X, 09/2013, Volume 31, Issue 27, pp. 3327 - 3334
Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Adenocarcinoma - pathology | Adenocarcinoma of Lung | Cisplatin - pharmacokinetics | Glutamates - adverse effects | Guanine - analogs & derivatives | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | ErbB Receptors - genetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Neoplasm Metastasis | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Guanine - adverse effects | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Guanine - pharmacokinetics | Adenocarcinoma - enzymology | Glutamates - pharmacokinetics | Adenocarcinoma - drug therapy | Pemetrexed | Afatinib | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Cisplatin - adverse effects | Glutamates - administration & dosage | Aged | Mutation | Guanine - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
by Martin J. van den Bent and Alba A. Brandes and Roy Rampling and Mathilde C.M. Kouwenhoven and Johan M. Kros and Antoine F. Carpentier and Paul M. Clement and Marc Frenay and Mario Campone and Jean-Francois Baurain and Jean-Paul Armand and Martin J.B. Taphoorn and Alicia Tosoni and Heidemarie Kletzl and Barbara Klughammer and Denis Lacombe and Thierry Gorlia
Journal of clinical oncology, ISSN 0732-183X, 03/2009, Volume 27, Issue 8, pp. 1268 - 74
Erlotinib Hydrochloride | Humans | Middle Aged | Antineoplastic Agents/therapeutic use | Male | Dacarbazine/adverse effects | Quinazolines/adverse effects | Glioblastoma/drug therapy | PTEN Phosphohydrolase/analysis | Neoplasm Recurrence, Local/drug therapy | Adolescent | Adult | Carmustine/adverse effects | Female | Aged | Receptor, Epidermal Growth Factor/genetics | Brain Neoplasms/drug therapy | Life Sciences & Biomedicine | Oncology | Science & Technology | Neurology | Biological and medical sciences | Medical sciences | Tumors of the nervous system. Phacomatoses | Tumors | Receptor, Epidermal Growth Factor - genetics | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | PTEN Phosphohydrolase - analysis | Neoplasm Recurrence, Local - drug therapy | Quinazolines - pharmacokinetics | Antineoplastic Agents - therapeutic use | Brain Neoplasms - drug therapy | Carmustine - therapeutic use | Quinazolines - therapeutic use | Dacarbazine - analogs & derivatives | Quinazolines - adverse effects | Glioblastoma - drug therapy | Carmustine - adverse effects | Index Medicus | Original Reports | Neur1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Synthesis and in vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: Search for anticancer agent
by Noolvi, Malleshappa N and Patel, Harun M and Bhardwaj, Varun and Chauhan, Ankit
European journal of medicinal chemistry, ISSN 0223-5234, 06/2011, Volume 46, Issue 6, pp. 2327 - 2346
Quinoxaline | Antitumor agents | Rational design | Synthesis 2-furano-4(3H)-quinazolinones | QSAR | Diamides (open ring quinazolines) | Biological and medical sciences | General aspects | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Quinazolines - chemical synthesis | Stereoisomerism | Antineoplastic Agents - chemical synthesis | Humans | Quinoxalines - chemistry | Structure-Activity Relationship | Antineoplastic Agents - chemistry | Dose-Response Relationship, Drug | Quinoxalines - pharmacology | Cell Line, Tumor | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Molecular Structure | Quinazolines - pharmacology | Quinoxalines - chemical synthesis | Quinazolines - chemistry | Drug Screening Assays, Antitumor | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Phosphatidylinositol 3-kinase inhibition by Copanlisib in relapsed or refractory indolent lymphoma
by Dreyling, Martin and Santoro, Armando and Mollica, Luigina and Leppä, Sirpa and Follows, George A and Lenz, Georg and Kim, Won Seog and Nagler, Arnon and Panayiotidis, Panayiotis and Demeter, Judit and Öcan, Muhit and Kosinova, Marina and Bouabdallah, Krimo and Morschhauser, Franck and Stevens, Don A and Trevarthen, David and Giurescu, Marius and Cupit, Lisa and Liu, Li and Köchert, Karl and Seidel, Henrik and Peña, Carol and Yin, Shuxin and Hiemeyer, Florian and Garcia-Vargas, Jose and Childs, Barrett H and Zinzani, Pier Luigi
Journal of clinical oncology, ISSN 0732-183X, 12/2017, Volume 35, Issue 35, pp. 3898 - 3905
Life Sciences & Biomedicine | Oncology | Science & Technology | Isoenzymes | Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Humans | Middle Aged | Transcriptome | Male | Protein Kinase Inhibitors - adverse effects | Lymphoma, B-Cell - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Lymphoma, B-Cell - enzymology | Pyrimidines - adverse effects | Quinazolines - adverse effects | Aged, 80 and over | Adult | Female | Aged | Lymphoma, B-Cell - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Synthesis, biological evaluation and molecular docking of novel series of spiro [(2H,3H) quinazoline-2,1′- cyclohexan]-4(1H)- one derivatives as anti-inflammatory and analgesic agents
by Amin, K.M and Kamel, M.M and Anwar, M.M and Khedr, M and Syam, Y.M
European journal of medicinal chemistry, ISSN 0223-5234, 2010, Volume 45, Issue 6, pp. 2117 - 2131
Ulcerogenic effect | Analgesic | Cyclooxygenase-2 | Spiro [(2H,3H) quinazoline-2,1′-cyclohexan]-4(1H)-one | Molecular docking | Antiinflammatory | Biological and medical sciences | Medical sciences | Neuropharmacology | Analgesics | Pharmacology. Drug treatments | Bones, joints and connective tissue. Antiinflammatory agents | Quinazolines - chemical synthesis | Analgesics - pharmacology | Molecular Conformation | Analgesics - metabolism | Male | Anti-Inflammatory Agents - metabolism | Anti-Inflammatory Agents - adverse effects | Cyclohexanones - adverse effects | Quinazolines - metabolism | Analgesics - chemical synthesis | Cyclohexanes - chemistry | Female | Cyclohexanones - chemical synthesis | Analgesics - adverse effects | Anti-Inflammatory Agents - pharmacology | Cyclooxygenase 2 - chemistry | Models, Molecular | Rats | Edema - drug therapy | Cyclohexanones - pharmacology | Ulcer - chemically induced | Animals | Cyclooxygenase 2 - metabolism | Quinazolines - adverse effects | Anti-Inflammatory Agents - chemical synthesis | Quinazolines - pharmacology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights